HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance.

Abstract
Cisplatin-based chemotherapy frequently resulted in acquired resistance. The underpinning mechanism of such resistance remains obscure especially in relation to autophagic response. This study thus investigated the role of autophagy in the anticancer activity of cisplatin in human esophageal cancer cells with acquired cisplatin resistance. In response to cisplatin treatment, EC109 cells exhibited substantial apoptosis and senescence whereas cisplatin-resistant EC109/CDDP cells exhibited resistance. In this respect, cisplatin increased ERK phosphorylation whose inhibition by MEK inhibitor significantly attenuated the cytotoxic and cytostatic effect of cisplatin. Notably, cisplatin preferentially induces autophagy in EC109/CDDP cells but not in EC109 cells. Moreover, the induction of autophagy was accompanied by the suppression of mTORC1 activity. Abolition of autophagy by pharmacological inhibitors or knockdown of ATG5/7 re-sensitized EC109/CDDP cells. Co-administration of an autophagy inhibitor chloroquine and cisplatin significantly suppressed tumor growth whereas cisplatin monotherapy failed to elicit anticancer activity in nude mice xenografted with EC109/CDDP cells. To conclude, our data implicate autophagic response as a key mechanism of acquired resistance to cisplatin, suggesting that autophagy is a novel target to improve therapy efficiency of cisplatin toward human esophageal cancers with acquired resistance.
AuthorsLe Yu, Chunping Gu, Desheng Zhong, Lili Shi, Yi Kong, Zhitao Zhou, Shuwen Liu
JournalCancer letters (Cancer Lett) Vol. 355 Issue 1 Pg. 34-45 (Dec 01 2014) ISSN: 1872-7980 [Electronic] Ireland
PMID25236911 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • ATG5 protein, human
  • Antineoplastic Agents
  • Autophagy-Related Protein 5
  • Microtubule-Associated Proteins
  • Multiprotein Complexes
  • Protein Kinase Inhibitors
  • Chloroquine
  • Mechanistic Target of Rapamycin Complex 1
  • TOR Serine-Threonine Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • Atg7 protein, human
  • Autophagy-Related Protein 7
  • Ubiquitin-Activating Enzymes
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Autophagy (drug effects)
  • Autophagy-Related Protein 5
  • Autophagy-Related Protein 7
  • Cell Line, Tumor
  • Cellular Senescence (drug effects)
  • Chloroquine (pharmacology)
  • Cisplatin (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • Enzyme Activation
  • Esophageal Neoplasms (drug therapy, genetics, metabolism, pathology)
  • Extracellular Signal-Regulated MAP Kinases (antagonists & inhibitors, metabolism)
  • Female
  • Humans
  • Mechanistic Target of Rapamycin Complex 1
  • Mice, Inbred BALB C
  • Mice, Nude
  • Microtubule-Associated Proteins (antagonists & inhibitors, genetics, metabolism)
  • Multiprotein Complexes (metabolism)
  • Phosphorylation
  • Protein Kinase Inhibitors (pharmacology)
  • RNA Interference
  • Signal Transduction (drug effects)
  • TOR Serine-Threonine Kinases (metabolism)
  • Time Factors
  • Transfection
  • Tumor Burden (drug effects)
  • Ubiquitin-Activating Enzymes (antagonists & inhibitors, genetics, metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: